Cisplatin in Breast Cancer Treatment
Author Information
Author(s): P. Willemse, D.Th. Sleijfer, N.H. Mulder, E.G.E. de Vries
Primary Institution: Groningen University Hospital
Hypothesis
The study investigates the efficacy and toxicity of cisplatin as a treatment for advanced breast cancer.
Conclusion
Cisplatin showed moderate efficacy but resulted in unexpectedly severe toxicity, leading to the termination of the study.
Supporting Evidence
- Two patients achieved a complete response to treatment.
- Three patients were stable, while two had progressive disease.
- All patients experienced grade 3-4 nausea and vomiting.
- Two patients had to stop treatment due to deteriorating renal function.
- One patient died from leucopenia related fever.
Takeaway
Doctors tried a cancer drug called cisplatin on 8 women with advanced breast cancer, but it made them very sick, so they stopped using it.
Methodology
Eight postmenopausal patients were treated with cisplatin 80 mg/m2 intravenously every 3 weeks.
Limitations
The study was terminated due to severe toxicity, limiting the ability to assess long-term efficacy.
Participant Demographics
All participants were postmenopausal women with advanced or recurrent breast cancer.
Want to read the original?
Access the complete publication on the publisher's website